A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. (December 2015)

• Record Type: Journal Article
• Authors: Abad‐Gurumeta, A.; Ripollés‐Melchor, J.; Casans‐Francés, R.; Espinosa, A.; Martínez‐Hurtado, E.; Fernández‐Pérez, C.; Ramírez, J. M.; López‐Timoneda, F.; Calvo‐Vecino, J. M.
• Is Part Of: Anaesthesia. Volume 70:Number 12(2015:Dec.)
• Page Start: 1441
• Page End: 1452
• Publication Date: 2015-12
• Subjects: Anesthesia -- Periodicals; 617.96
• DOI: 10.1111/anae.13277
• Languages: English
• ISSNs: 0003-2409

Abstract

Summary: We reviewed systematically sugammadex vs neostigmine for reversing neuromuscular blockade. We included 17 randomised controlled trials with 1553 participants. Sugammadex reduced all signs of residual postoperative paralysis, relative risk (95% CI) 0.46 (0.29–0.71), p = 0.0004 and minor respiratory events, relative risk (95% CI) 0.51 (0.32–0.80), p = 0.0034. There was no difference in critical respiratory events, relative risk (95% CI) 0.13 (0.02–1.06), p = 0.06. Sugammadex reduced drug‐related side‐effects, relative risk (95% CI) 0.72 (0.54–0.95), p = 0.02. There was no difference in the rate of postoperative nausea or the rate of postoperative vomiting, relative risk (95% CI) 0.94 (0.79–1.13), p = 0.53, and 0.87 (0.65–1.17), p = 0.36 respectively.